raloxifene hydrochloride has been researched along with Heart Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budoff, MJ | 1 |
| Amewou-Atisso, MG; Barrett-Connor, E; Collins, P; Daniels, LB; Grady, D; Mitlak, BH; Mosca, L; Wenger, NK | 1 |
| Ettinger, B; Grove, MR; Hammond, CS; Hebert, GM; Moncur, MM; Pressman, AR; Ray, GT; Tosteson, AN | 1 |
| Lush, DT | 1 |
| Arnaud, CD; Chiu, KM; Roe, EB | 1 |
| Body, JJ; Sternon, J | 1 |
| Moore, HC | 1 |
| Kamp, O; Kenemans, P; Mijatovic, V; Neele, SJ; Netelenbos, JC; Pines, A; van der Mooren, MJ; Vogelvang, TE | 1 |
3 review(s) available for raloxifene hydrochloride and Heart Diseases
| Article | Year |
|---|---|
Preventing heart disease and cancer. What randomized, primary-prevention studies show.
Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Coronary Disease; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selenium; Tamoxifen; Vitamin E | 1999 |
Selective estrogen receptor modulators and postmenopausal health.
Topics: Breast Neoplasms; Chemoprevention; Dementia; Female; Fractures, Bone; Heart Diseases; Humans; Lipoproteins; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health | 2000 |
Treatment of estrogen deficiency symptoms in women surviving breast cancer.
Topics: Breast Neoplasms; Estrogen Replacement Therapy; Female; Heart Diseases; Humans; Menopause; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Survivors | 1998 |
2 trial(s) available for raloxifene hydrochloride and Heart Diseases
| Article | Year |
|---|---|
Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.
Topics: Age Factors; Aged; Bone Density Conservation Agents; Chi-Square Distribution; Comorbidity; Diabetes Complications; Double-Blind Method; Female; Heart Diseases; Humans; Kaplan-Meier Estimate; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prevalence; Prognosis; Proportional Hazards Models; Prospective Studies; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Sex Factors; Time Factors | 2013 |
Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.
Topics: Double-Blind Method; Echocardiography; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Heart Diseases; Humans; Medroxyprogesterone Acetate; Middle Aged; Placebos; Raloxifene Hydrochloride; Systole; Ventricular Function, Left | 2002 |
5 other study(ies) available for raloxifene hydrochloride and Heart Diseases
| Article | Year |
|---|---|
Diabetes mellitus in women can be RUTHless: lessons from the Raloxifene Use for The Heart (RUTH) Trial.
Topics: Bone Density Conservation Agents; Diabetes Complications; Female; Heart Diseases; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride | 2013 |
Early discontinuation of treatment for osteoporosis.
Topics: Alendronate; Bone Diseases, Metabolic; Breast Neoplasms; California; Cohort Studies; Estrogen Replacement Therapy; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Interviews as Topic; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Treatment Refusal | 2003 |
Smart estrogens may decrease heart-attack risk.
Topics: Estrogen Antagonists; Estrogen Replacement Therapy; Female; Heart Diseases; Humans; Lipids; Piperidines; Raloxifene Hydrochloride | 1998 |
[Raloxifene (Celvista, Evista)].
Topics: Arteriosclerosis; Bone and Bones; Breast Neoplasms; Controlled Clinical Trials as Topic; Endometrium; Female; Fractures, Bone; Heart Diseases; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism; Uterine Hemorrhage | 2000 |
Managing menopause after breast cancer: balancing risks and benefits.
Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcitonin; Climacteric; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Heart Diseases; Humans; Menopause; Menopause, Premature; Neoplasm Recurrence, Local; Osteoporosis; Pregnancy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2001 |